title: [Uncomplicated lower urinary tract infections in females--clinical aspects, aetiology and antimicrobial resistance epidemiology. Results of the ARESC (Antimicrobial Resistance Epidemiological Survey on Cystitis) study in Poland and their implications for empiric therapy].
abstract: The Polish results of the international ARESC study are reported concerning clinical aspects, epidemiology, and antimicrobial susceptibility of uropathogens.
  
  
  METHODS
  Patients between 18 and 65 years with symptoms of uncomplicated cystitis were consecutively enrolled and investigated clinically including urinalysis and urine culture. Uropathogens were identified and their susceptibility was tested for nine antimicrobials
  
  
  RESULTS
  In Poland a total of 212 patients were enrolled and 119 uropathogens from 118 patients were identified. Escherichia coli was the most frequent (90; 75.6%), followed by Staphylococcus saprophyticus (5; 4.2%), Staphylococcus aureus (4; 3.4%), Proteus mirabilis (4; 3.4%), Klebsiella pneumoniae (3; 2.5%), E. coli showed the highest rate of susceptibility to fosfomycin (98.9%) followed by mecillinam (97.8%), nitrofurantoin (92.2%), and ciprofloxacin (92.2%). The lowest rate was found for ampicillin (40.0%) followed by cotrimoxazole (80.0%). For the total spectrum the order was fosfomycin (97.1%), ciprofloxacin (93.1%), and nitrofurantoin (85.2%). The lowest rates were found again for ampicillin (43.2%) and cotrimoxazole (80.7%).
  
  
  CONCLUSIONS
  The results indicate that fosfomycin, ciprofloxacin, nitrofurantoin and amoxicillin/clavulanate have preserved their good in vitro activity (> 80%) against both E. coli and the total spectrum of uropathogens.
authors.affiliation: Zakład Medycyny Rodzinnej i Pielgniarstwa Srodowiskowego, Uniwersytet Medyczny w Białymstoku. schlabicz@poczta.onet.pl
authors.forename: Sławomir
authors.initials: S
authors.lastname: Chlabicz
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Leszczynska
authors.forename: Witold
authors.initials: W
authors.lastname: Lukas
authors.forename: Laura
authors.initials: L
authors.lastname: Gualco
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Schito
authors.forename: Kurt G
authors.initials: KG
authors.lastname: Naber
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003556:Cystitis / Q000453:epidemiology; D024881:Drug Resistance, Bacterial; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011044:Poland; D014552:Urinary Tract Infections / Q000382:microbiology; D016387:Women's Health; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents